OncoMatch/Clinical Trials/NCT05618366
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Is NCT05618366 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Venetoclax and Tazemetostat for lymphoma, non-hodgkin.
Treatment: Venetoclax · Tazemetostat — The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venetoclax to give with tazemetostat to people with R/R NHL; what types of side effects do people with R/R NHL get when taking venetoclax with tazemetostat; and what effects does this combination have on R/R NHL. Participants will need to take pills by mouth every day and regularly come to the clinic for blood work and imagining to monitor side effects and cancer progression. Participants may receive study drugs for up to 24 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any systemic therapy for lymphoma
Subjects must have received at least two prior lines of therapy for lymphoma with evidence of disease progression.
Cannot have received: tazemetostat (tazemetostat)
Prior exposure to either tazemetostat or venetoclax
Cannot have received: venetoclax (venetoclax)
Prior exposure to either tazemetostat or venetoclax
Lab requirements
Blood counts
ANC ≥ 1 x 10^9/L without growth factor support for at least 14 days; Platelet count ≥75 x 10^9/L, evaluated at least 7 days after last platelet transfusion; Hemoglobin ≥9.0g/dL, independent of transfusion
Kidney function
Calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault equation)
Liver function
Total bilirubin < 1.5 x ULN, except Gilbert's disease; ALT and AST < 3 x ULN
Patients must have adequate organ and bone marrow function: * Absolute neutrophil count (ANC) ≥ 1 x 10^9/L without growth factor support (filgrastim or pegfilgrastim) for at least 14 days * Platelet count ≥75 x 10^9/L, evaluated at least 7 days after last platelet transfusion * Hemoglobin ≥9.0g/dL, independent of transfusion * Total bilirubin < 1.5 x's the upper limit of the normal range (ULN), except Gilbert's disease * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x's ULN. * Calculated creatinine clearance according to the Cockcroft-Gault equation. ≥ 40 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Weill Cornell Medicine/NewYork-Presberteryian Hospital · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify